Loading
Life sciences · Journal article
Journal of Nanobiotechnology · October 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Malignant cancers, which are highly aggressive and therapeutically resistant with limited treatment approaches, dual piezo-chemodynamic therapy to kill cancers both sharply under ultrasound (US) stimuli and persistently under acid conditions would be an ideal choice. To achieve tumor microenvironment (TME)-activated and size-minimized precision cancer theranostics for highly effective treatment outcomes remains a significant challenge. Herein, chitosan-functionalized Mn-doped bismuth ferrite (CMBFO) nanoparticles are developed for TME-responsive magnetic resonance imaging (MRI)-guided chemodynamic therapy (CDT) and piezodynamic therapy (PZDT) against subcutaneous tumors. The chitosan functionalization not only improves biocompatibility and cellular uptake but also facilitates pH-triggered Mn 2+ release through protonation of NH 2 groups, leading to loosening of the coating. This process endows T 2 -MRI contrast and activates the Fenton-like reaction to generate reactive oxygen species (ROS) for CDT. Concurrently, US stimulation induces the piezocatalysis, producing ROS for PZDT. This dual ROS-generating system demonstrates synergistic effects. In vitro and in vivo studies show that CMBFO accumulates specifically in the TME, with pH-triggered MRI signal peaking at 5.1 pH and 6 h post-injection, achieving over 95% tumor cell lethality under US with negligible systemic toxicity. This study establishes CMBFO as a multifunctional nanoplatform integrating tumor-specific MRI, pH-responsive drug release, and dual ROS-mediated therapy, offering a promising strategy for effective and safe tumor treatment.